Frontier Bets $52m On Potential Rival To Gilead's Veklury
Frontier Biotechnologies is seeking to enroll roughly 1,200 hospitalized COVID patients in an international Phase II/III clinical trial to evaluate its bofutrelvir (FB2001) in competition with Gilead’s Veklury.
You may also be interested in...
As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.
Unexpected protocol changes and a single-blind design for a Phase III head-to-head trial seem to have played to the advantage of Junshi’s oral derivative of Gilead’s antiviral remdesivir in COVID-19.
The US- and China-based biotech is expanding three oncology-centered clinical studies of two TGF-1/COX-2-targeted siRNA drug candidates from the US into China.